Banner News


Singapore, November 29, 2021 – In response to the new variant strain Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on November 29th, 2021.


According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay is capable of detecting the new variant strain correctly.


As the analysis result was based on limited sequence data currently published, we will continue to monitor and collect the sequence data to verify the impact of this new emerging variant on assay performance.


Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly.

Another four Variants of Concern (VOC):

Alpha variant: known as B.1.1.7 or UK variant

Beta variant: known as B.1.351 or South Africa variant

Gamma variant: known as P.1 or Brazil variant

Delta variant: known as B.1.617.2 or Indian variant


Two Variants of Interest (VOI):

Lambda variant: known as C.37 or Peru variant

Mu variant: known as B.1.621 or Colombia variant


The other six variants:

Eta variant: known as B.1.525

Iota variant: known as B.1.526

Kappa variant: known as B.1.617.1 or Indian variant

Zeta variant: known as P.2 or Brazil variant

Epsilon variant: known as B.1.427/B.1.429 or United States variant

Indian variant: known as B.1.617.3

 LINE ALBUM SARS CoV 2 Gen2 211130 copy












About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.